During the research period, a total of 1288 urinary samples were collected of which 398 (30.9%) showed positive results and others appeared negative. Subsequent analysis of positive growth samples indicated that the ages of most infected people (50.5%) were between 21-40 years, followed by 41-60 years, <20 years, and >60 years (Fig. 1) where most of the infected people were female (72.6%)(Table 1).
Table 1: Prevalence of UTI based on gender
Sex
|
Number of Sample
|
Percentage of sample (%)
|
Female
|
289
|
72.6 %
|
Male
|
109
|
27.4 %
|
Total
|
398
|
100 %
|
Organisms identified according to biochemical and microbiological tests were mostly E. coli (82.86%), followed by Enterococcus faecalis, Klebsiella sp, Pseudomonas aeruginosa, and Proteus sp (Fig. 2).
Our study presented that only Meropenem (97.8%) was highly sensitive while four antibiotics Clindamycin (98.7 %), Cefixime (98.4 %), Cefuroxime (84.5 %), and Cephradine (79.0 %) were highly resistant against E. coli. The remaining antibiotics, Amoxicillin, Azithromycin, Ceftriaxone, Ciprofloxacin, Cefepime, Gentamicin, Nitrofurantoin, Levofloxacin, and Trimethoprim, were moderately sensitive to E. coli (Fig. 3).
For Enterococcus faecalis, the most sensitive antibiotics were Meropenem (100%), whereas higher antibiotic resistance was found against Cephradine (100%), Clindamycin (100%), Cefixime (96.9%), Ceftriaxone (87.8%), Cefuroxime (78.8%), and Trimethoprim (75.7%). The remaining antibiotics were moderately sensitive against Enterococcus faecalis (Fig. 4).
Highly sensitive antibiotics against Klebsiella sp. found in our study were Meropenem (100%), Cefepime (95.4%), Gentamicin (95.4%), Nitrofurantoin (95.4%), and Ciprofloxacin (81.8%). In this case, highly resistant antibiotics were Cefixime (100.0%), Cephradine (100.0%), Cefuroxime (100.0%), Clindamycin (100.0%), Ceftriaxone (95.4%), Amoxicillin (86.3%), and Levofloxacin (86.3%). Trimethoprim (90.9%) and Azithromycin (86.3%) were moderately sensitive against Klebsiella sp (Fig. 5).
For Pseudomonas aeruginosa, higher sensitivity was found in Meropenem (100%). On the other hand, most of the used antibiotics Cefixime (100%), Cephradine (100%), Cefuroxime (100%), Clindamycin (100%), Nitrofurantoin (100%), Ceftriaxone (90.9%), Trimethoprim (81.8%) and Cefepime (63.6%) were resistant against Pseudomonas aeruginosa. Amoxicillin, Azithromycin, Ciprofloxacin, Gentamicin, and Levofloxacin were moderately susceptible against Pseudomonas aeruginosa (Fig. 6).
For Proteus sp, only Meropenem (100%) and Nitrofurantoin (75%) were highly sensitive; most of the used antibiotics Cefixime (100%), Cephradine (100%), Ceftriaxone (100%), Cefuroxime (100%), Clindamycin (100%), Cefepime (100%), Trimethoprim (100%), and Levofloxacin (75.0%) were highly resistant and remaining antibiotics Gentamicin (100%), Azithromycin (75%), and Ciprofloxacin (75%) were moderately susceptible against Proteus sp (Fig. 7).
Overall antimicrobial susceptibility study of different isolates from urinary tract infections (UTIs) revealed that most of the antibiotics Clindamycin (98.9%), Cefixime (98.50%), Cefuroxime (87.43%), Cephradine (83.1%), Trimethoprim (64.9%), and Ceftriaxone (63.1%) were highly resistant against E. coli, Enterococcus faecalis, Pseudomonas aeruginosa, Klebsiella sp, and Proteus sp. The remaining experimental antibiotics were moderately sensitive to all isolated pathogens while only Meropenem showed the highest sensitivity (98.25%) to all tested pathogens (Table 2).
Table 2: Overall antibiotic sensitivity pattern against UTI pathogens
Antibiotics Name
|
Intermediate (I)
|
Resistance (R)
|
Sensitive (S)
|
No.
|
Percentage
|
No.
|
Percentage
|
No.
|
Percentage
|
Amoxicillin
|
120
|
30.15%
|
170
|
42.71%
|
108
|
27.14%
|
Azithromycin
|
128
|
32.17%
|
141
|
35.43%
|
129
|
32.42%
|
Cefixime
|
06
|
1.50%
|
392
|
98.50%
|
0
|
0%
|
Cephradine
|
37
|
9.30%
|
330
|
83.1%
|
31
|
7.78%
|
Ceftriaxone
|
102
|
25.7%
|
251
|
63.1%
|
45
|
11.30%
|
Cefuroxime
|
45
|
11.31%
|
348
|
87.43%
|
05
|
1.26%
|
Ciprofloxacin
|
168
|
42.2%
|
108
|
27.2%
|
122
|
30.65%
|
Clindamycin
|
02
|
0.51%
|
394
|
98.9%
|
02
|
0.51%
|
Cefepime
|
106
|
26.64%
|
182
|
45.8%
|
110
|
27.64%
|
Gentamicin
|
130
|
32.67%
|
117
|
29.4%
|
151
|
37.94%
|
Meropenem
|
07
|
1.76%
|
00
|
00%
|
391
|
98.25%
|
Nitrofurantoin
|
95
|
23.9%
|
168
|
42.3%
|
135
|
33.92%
|
Levofloxacin
|
75
|
18.85%
|
108
|
27.13%
|
215
|
54.0%
|
Trimethoprim
|
84
|
21.1%
|
258
|
64.9%
|
56
|
14.0%
|